Cynomolgus Monkey TIM-3 ELISA

Catalog Number:
DIY2296Y
Availability:
In stock
Application:
ELISA
100% Homology:
Macaca fascicularis (crab-eating macaque)

Components

UsageQuantityComponentSize
Detection Antibody50 µgKPB2295Y-050
Standard5 µgRP1890Y-005
Capture Antibody100 µgKP2294Y-1001 Pack (<= 10 Plates)
Capture Antibody100 µg X 2KP2294Y-1001 Pack (<= 20 Plates)
  • The Cynomolgus Monkey TIM-3 (T cell Immunoglobulin and Mucin-domain containing-3, also known as HAVCR2) ELISA is designed for the quantitative measurement of TIM-3 in cell culture supernatants from Cynomolgus monkeys (Macaca fascicularis) and can also be used to measure soluble TIM-3 in additional biological sample types reported in the literature, including serum, plasma, and tissue lysates, with minor protocol modifications recommended to optimize performance across different matrices. The Cynomolgus monkey TIM-3 protein sequence is highly conserved and functionally comparable to that of Rhesus monkey (Macaca mulatta), enabling use in non-human primate translational models. TIM-3 is an immune checkpoint receptor expressed primarily on activated T cells, exhausted CD8⁺ T cells, Th1 cells, regulatory T cells, dendritic cells, and certain innate immune cells, where it regulates immune tolerance and T cell exhaustion through interaction with ligands such as galectin-9, phosphatidylserine, and CEACAM1. In healthy non-human primates, soluble TIM-3 levels are typically low or near the limit of detection, but concentrations may increase during chronic viral infection, tumor progression, inflammatory disease, or immunotherapy studies, reflecting immune activation and exhaustion dynamics. In preclinical and translational research, Cynomolgus monkey TIM-3 serves as an important biomarker for immune checkpoint activation, T cell dysfunction, chronic infection models, oncology studies, and evaluation of immune-modulating biologics. The ELISA kit contains a capture antibody, detection antibody, and recombinant Cynomolgus monkey TIM-3 protein standard validated for use together in an ELISA format; kit components are not supplied in matched quantities and may be purchased separately. This product is for research use only, not for use in diagnostic or therapeutic procedures, and is manufactured in the USA.
Storage Conditions2°C to 8°C or -20°C
Country Of OriginUSA
Cynomolgus Monkey (Macaca fascicularis) TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3, also known as HAVCR2) is an immune checkpoint receptor that regulates T cell activation, immune tolerance, and inflammatory responses in nonhuman primates. TIM-3 is a member of the TIM (T cell immunoglobulin and mucin domain) family of immune regulatory proteins, which includes TIM-1, TIM-3, and TIM-4, molecules that modulate immune activation and maintain immune homeostasis. In cynomolgus monkeys, TIM-3 is expressed on activated CD4⁺ and CD8⁺ T lymphocytes, natural killer (NK) cells, dendritic cells, and macrophages, where it functions primarily as a negative regulator of immune responses. Interaction of TIM-3 with ligands such as galectin-9, phosphatidylserine, and HMGB1 delivers inhibitory signals that suppress T cell proliferation, cytokine production, and cytotoxic activity, helping prevent excessive immune-mediated tissue damage. Because cynomolgus monkeys are widely used in preclinical infectious disease and immunology research, TIM-3 is frequently studied in models of chronic viral infections (such as SIV/HIV), tuberculosis, and cancer, where increased TIM-3 expression is associated with T cell exhaustion and impaired immune responses. As a key immune checkpoint molecule, cynomolgus monkey TIM-3 is important for studies of immune regulation, host–pathogen interactions, and evaluation of immunotherapies targeting checkpoint pathways, providing translational insight relevant to human disease.

Please choose a size to see price


Reagents for Animal Model and Animal Health Research

Kingfisher Biotech, Inc.
1000 Westgate Drive
Suite 123
Saint Paul, MN 55114

Phone: 651-646-0089
Fax: 651-646-0095

Animal Antibodies

Newsletter

"